RegulatoryMay 22, 2026, 08:02 AM
Anavex Life Sciences Receives Nasdaq Delinquency Notice
AI Summary
Anavex Life Sciences Corp. announced it received a delinquency notification from Nasdaq on May 20, 2026. The notice states the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to timely file its Form 10-Q for the quarterly period ended March 31, 2026. Anavex has until July 20, 2026, to submit a plan to regain compliance, and the company is actively working to complete the filing and submit the plan. This notification does not immediately affect the company's Nasdaq listing.
Key Highlights
- Anavex Life Sciences received a delinquency notification from Nasdaq on May 20, 2026.
- The notice indicates non-compliance with Nasdaq Listing Rule 5250(c)(1).
- The non-compliance is due to the company's inability to timely file its Form 10-Q for the quarter ended March 31, 2026.
- Anavex has until July 20, 2026, to submit a plan to regain compliance.
- The company is working to complete and file the Form 10-Q and submit a compliance plan.
- The notification has no immediate effect on the company's common stock listing on Nasdaq.
Price Impact
More from AVXL